Comparative potencies of 3,4‐methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5‐HT transport in mammalian cell lines
- 1 December 2007
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 152 (7) , 1121-1130
Abstract
Background and purpose: Illegal ‘ecstasy’ tablets frequently contain 3,4‐methylenedioxymethamphetamine (MDMA)‐like compounds of unknown pharmacological activity. Since monoamine transporters are one of the primary targets of MDMA action in the brain, a number of MDMA analogues have been tested for their ability to inhibit [3H]noradrenaline uptake into rat PC12 cells expressing the noradrenaline transporter (NET) and [3H]5‐HT uptake into HEK293 cells stably transfected with the 5‐HT transporter (SERT).Experimental approach: Concentration–response curves for the following compounds at both NET and SERT were determined under saturating substrate conditions: 4‐hydroxy‐3‐methoxyamphetamine (HMA), 4‐hydroxy‐3‐methoxymethamphetamine (HMMA), 3,4‐methylenedioxy‐N‐hydroxyamphetamine (MDOH), 2,5‐dimethoxy‐4‐bromophenylethylamine (2CB), 3,4‐dimethoxymethamphetamine (DMMA), 3,4‐methylenedioxyphenyl‐2‐butanamine (BDB), 3,4‐methylenedioxyphenyl‐N‐methyl‐2‐butanamine (MBDB) and 2,3‐methylenedioxymethamphetamine (2,3‐MDMA).Key results: 2,3‐MDMA was significantly less potent than MDMA at SERT, but equipotent with MDMA at NET. 2CB and BDB were both significantly less potent than MDMA at NET, but equipotent with MDMA at SERT. MBDB, DMMA, MDOH and the MDMA metabolites HMA and HMMA, were all significantly less potent than MDMA at both NET and SERT.Conclusions and implications: This study provides an important insight into the structural requirements of MDMA analogue affinity at both NET and SERT. It is anticipated that these results will facilitate understanding of the likely pharmacological actions of structural analogues of MDMA.British Journal of Pharmacology (2007) 152, 1121–1130; doi:10.1038/sj.bjp.0707473; published online 24 September 2007Keywords
This publication has 57 references indexed in Scilit:
- Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine‐Type DrugsAnnals of the New York Academy of Sciences, 2006
- Pharmacological content of tablets sold as “ecstasy”: Results from an online testing serviceDrug and Alcohol Dependence, 2006
- Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issuesDrug and Alcohol Review, 2006
- L-Tyrosine Contributes to (+)-3,4-Methylenedioxymethamphetamine-Induced Serotonin DepletionsJournal of Neuroscience, 2006
- Pharmacological Characterization of Ecstasy Synthesis Byproducts with Recombinant Human Monoamine TransportersThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Serotonergic Neurotoxic Metabolites of Ecstasy Identified in Rat BrainThe Journal of Pharmacology and Experimental Therapeutics, 2005
- N‐methyl‐1‐(1,3‐benzodioxol‐5‐yl)‐2‐butanamine (MBDB): its properties and possible risksAddiction Biology, 2000
- Structure-activity relationships of BDB and its monomethyl and dimethyl derivativesPharmacology Biochemistry and Behavior, 1995
- Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from salinePharmacology Biochemistry and Behavior, 1989
- Synthesis of erbstatin, a naturally occurring inhibitor of tyrosine-specific protein kinaseThe Journal of Organic Chemistry, 1987